On Thursday, President Donald Trump announced a new drug price deal with Regeneron, the latest company to agree to a new price policy push.

Regeneron is the last of 17 companies the administration pressed to commit to the "most favored nation" policy.

Regeneron is the latest in a string of major drugmakers to make pricing concessions for new and existing medicines under agreements with Trump.